BioCentury
ARTICLE | Clinical News

INCB7839: Development discontinued

November 7, 2011 8:00 AM UTC

Incyte disclosed in its 3Q11 earnings that it discontinued development of INCB7839 to treat metastatic breast cancer. Incyte said the decision was based on an analysis of tissue samples from >300 brea...